Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma.
Basal cell carcinoma
Hedgehog pathway
Vismodegib
Journal
Current problems in cancer
ISSN: 1535-6345
Titre abrégé: Curr Probl Cancer
Pays: United States
ID NLM: 7702986
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
09
12
2020
revised:
10
01
2021
accepted:
17
02
2021
pubmed:
26
4
2021
medline:
11
2
2022
entrez:
25
4
2021
Statut:
ppublish
Résumé
Basal cell carcinomas occur in up to 39% of Caucasian men and 28% of women. Rarely it can present a management dilemma in patients with neglected locally advanced disease of large dimension or involvement of critical structures. The Hedgehog pathway is constitutively active in almost all basal cell carcinomas and patients with Naevoid Basal Cell Carcinoma Syndrome have germline mutations in the Patched tumor suppressor gene, a Hedgehog pathway component, on chromosome 9q. This case describes an elderly patient with an untreated sporadic Basal cell carcinoma whose dimensions precluded local management approaches. The Hedgehog pathway inhibitor Vismodegib had a dramatic response allowing definitive treatment to be pursued.
Identifiants
pubmed: 33894989
pii: S0147-0272(21)00043-X
doi: 10.1016/j.currproblcancer.2021.100736
pii:
doi:
Substances chimiques
Anilides
0
Hedgehog Proteins
0
HhAntag691
0
Pyridines
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100736Informations de copyright
Copyright © 2021. Published by Elsevier Inc.